金吾财讯 | 艾伯维(ABBV)股价下行,截至发稿,跌12.22%,报175.18美元。
该股股价出现三年来最大跌幅,此前该公司治疗精神分裂症药物的两项中期试验未能达到其主要目标,这对该公司今年早些时候斥资 87 亿美元收购 Cerevel Therapeutics 造成了打击。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.